Dexcom Inc (DXCM) Files Form 4 Insider Selling : Jorge A Valdes Sells 32,000 Shares

Dexcom Inc (DXCM): Jorge A Valdes , CTO of Dexcom Inc sold 32,000 shares on Jul 11, 2016. The Insider selling transaction was reported by the company on Jul 12, 2016 to the Securities and Exchange Commission. The shares were sold at $79.36 per share for a total value of $2,539,564.75 , the company said in a SEC Form 4 Filing.

Other Insider transactions have been reported by the company according to SEC Form 4, on Jul 1, 2016, Jeffrey Moy (SVP, Operations) sold 4,557 shares at $80.00 per share price.On Jul 1, 2016, Andrew K Balo (EVP, Clinical and Regulatory) sold 5,000 shares at $78.10 per share price.Also, On Jun 27, 2016, Steven Robert Pacelli (EVP, Strategy & Corp. Dev.) sold 10,300 shares at $77.40 per share price.On Jun 21, 2016, Kevin R Sayer (President & CEO) sold 35,000 shares at $75.00 per share price.

DexCom: On Monday, Jul 11, 2016 heightened volatility was witnessed in DexCom which led to swings in the share price. The shares opened for trading at $79.49 and hit $79.82 on the upside , eventually ending the session at $79.4, with a gain of 0.67% or 0.53 points. The heightened volatility saw the trading volume jump to 7,35,130 shares. The 52-week high of the share price is $103.29 and the company has a market cap of $6,624 M . The 52-week low of the share price is at $47.92.

DexCom Money Flow Index Chart

Dexcom Inc. (Dexcom) is a medical device company. The Company is focused on the design development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products consist of DexCom G4 DexCom G4 PLATINUM and DexCom Share System. The DexCom G4 PLATINUM with Share uses a wireless connection between a patient’s receiver and an application on the patient’s iPhone to transmit glucose information to applications on the mobile devices of up to five designated recipients or followers who can remotely monitor a patient’s glucose information and receive alert notifications anywhere they have an Internet connection. SweetSpot’s data transfer service is a Medical Device Data System (MDDS) and allows researchers to control the transfer of data from certain diabetes devices to research tools and databases according to their own research workflows.

Leave a Reply

DexCom - Is it time to Sell?

Top Brokerage Firms are advising their investors on DexCom. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.